NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $1.02 -0.63 (-38.18%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.06 +0.04 (+3.82%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cognition Therapeutics Stock (NASDAQ:CGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$0.97▼$1.6150-Day Range$0.98▼$1.6852-Week Range$0.29▼$3.83Volume11.81 million shsAverage Volume1.34 million shsMarket Capitalization$91.29 millionP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingModerate Buy Company Overview Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease. CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease. In addition to its lead program, the company is advancing a preclinical pipeline aimed at expanding its approach to other neurodegenerative conditions. To support its global development efforts, Cognition Therapeutics collaborates with academic centers, contract research organizations and specialized clinical sites. Headquartered in Pittsburgh, Pennsylvania, Cognition Therapeutics conducts operations primarily in the United States, with ongoing clinical and regulatory activities in European markets. The company is led by co-founder and CEO Stephen M. Maccecchini, Ph.D., who oversees research, development and strategic partnerships. Cognition Therapeutics’ common stock is traded on the NASDAQ under the ticker symbol CGTX.AI Generated. May Contain Errors. Read More Cognition Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCGTX MarketRank™: Cognition Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 153rd out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCognition Therapeutics has a consensus price target of $3.33, representing about 226.8% upside from its current price of $1.02.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.32) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.07% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 7.72.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 17.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 5 news articles for Cognition Therapeutics this week, compared to 3 articles on an average week.Search Interest11 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows5 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership4.5 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Cognition Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $21,392.00 in company stock, which represents 0.0234% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,392.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Stock News HeadlinesCognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33%June 24 at 5:23 PM | msn.comCognition Therapeutics advances after FDA supports key elements of pivotal trial plan (CGTX)June 24 at 5:23 PM | msn.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page. | Weiss Ratings (Ad)Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB PsychosisJune 24 at 7:50 AM | quiverquant.comQCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesJune 24 at 7:30 AM | globenewswire.comCognition Therapeutics Shareholders Elect Directors, Ratify AuditorJune 18, 2026 | tipranks.comCognition Therapeutics Receives Notice of Allowance for Zervimesine Patent Application from USPTOJune 16, 2026 | quiverquant.comQCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045June 16, 2026 | globenewswire.comSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.35 at the beginning of 2026. Since then, CGTX shares have decreased by 24.4% and is now trading at $1.02. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Thursday, October 7th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Cognition Therapeutics' top institutional shareholders include Renaissance Technologies LLC (1.25%), Sigma Planning Corp (0.38%) and Essex Financial Services Inc. (0.04%). Insiders that own company stock include Lisa Ricciardi and John Brendan Doyle. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS). Company Calendar Last Earnings5/07/2026Today6/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CGTX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGTX CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees20Year Founded2007Price Target and Rating Average Price Target for Cognition Therapeutics$3.33 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+226.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.68% Return on Assets-53.07% Debt Debt-to-Equity RatioN/A Current Ratio5.92 Quick Ratio5.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book2.62Miscellaneous Outstanding Shares89,500,000Free Float79,555,000Market Cap$91.29 million OptionableNot Optionable Beta1.75 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:CGTX) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts